WO2002062368A8 - Method of inducing a ctl response - Google Patents

Method of inducing a ctl response

Info

Publication number
WO2002062368A8
WO2002062368A8 PCT/US2002/002033 US0202033W WO02062368A8 WO 2002062368 A8 WO2002062368 A8 WO 2002062368A8 US 0202033 W US0202033 W US 0202033W WO 02062368 A8 WO02062368 A8 WO 02062368A8
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
ctl response
inducing
mammal
disclosed
Prior art date
Application number
PCT/US2002/002033
Other languages
French (fr)
Other versions
WO2002062368A2 (en
WO2002062368A3 (en
Inventor
Thomas M Kundig
John J L Simard
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Priority to AU2002247023A priority Critical patent/AU2002247023A1/en
Publication of WO2002062368A2 publication Critical patent/WO2002062368A2/en
Publication of WO2002062368A3 publication Critical patent/WO2002062368A3/en
Publication of WO2002062368A8 publication Critical patent/WO2002062368A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Disclosed herein are methods for inducing an immunological CTL response to an antigen by sustained, regular delivery of the antigen to a mammal so that the antigen reaches the lymphatic system. Antigen is delivered at a level sufficient to induce an immunologic CTL response in a mammal and the level of the antigen in the mammal's lymphatic system is maintained over time sufficient to maintain the immunologic CTL response. Also disclosed is an article of manufacture for delivering an antigen that induces a CTL response in an animal.
PCT/US2002/002033 2001-02-02 2002-01-22 Method of inducing a ctl response WO2002062368A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002247023A AU2002247023A1 (en) 2001-02-02 2002-01-22 Method of inducing a ctl response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/776,232 2001-02-02
US09/776,232 US6977074B2 (en) 1997-07-10 2001-02-02 Method of inducing a CTL response

Publications (3)

Publication Number Publication Date
WO2002062368A2 WO2002062368A2 (en) 2002-08-15
WO2002062368A3 WO2002062368A3 (en) 2003-09-25
WO2002062368A8 true WO2002062368A8 (en) 2003-11-20

Family

ID=25106827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/002033 WO2002062368A2 (en) 2001-02-02 2002-01-22 Method of inducing a ctl response

Country Status (3)

Country Link
US (4) US6977074B2 (en)
AU (2) AU784923B2 (en)
WO (1) WO2002062368A2 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
PT991403E (en) * 1997-01-30 2003-08-29 Chiron Corp USE OF MICROPARTICLES WITH ADSORVED ANTIGEN TO STIMULATE IMMUNE RESPONSES
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US7279462B1 (en) * 1998-04-27 2007-10-09 Nevagen Llc Somatic transgene immunization and related methods
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
WO2000054839A2 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
ATE501175T1 (en) * 1999-04-27 2011-03-15 Nevagen Llc SOMATIC TRANSGENIC IMMUNIZATION AND RELATED METHODS
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
ATE346925T1 (en) * 2000-05-10 2006-12-15 Sanofi Pasteur Ltd IMMUNOGENIC POLYPEPTIDES ENCODED BY MAGE MINIGENE AND USES THEREOF
CN100589845C (en) * 2001-03-07 2010-02-17 麦康公司 Anti-neovasculature preparations for cancer
EP1448588A4 (en) 2001-10-23 2006-10-25 Psma Dev Company L L C Psma antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
GB0203276D0 (en) * 2002-02-12 2002-03-27 Novartis Ag Organic compounds
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
DE10225144A1 (en) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh Tumor-associated peptides binding to MHC molecules
CA2510238A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Cancer treatment using vaccine and high-dose cytokine
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
JP2007500251A (en) * 2003-06-13 2007-01-11 ベクトン・ディキンソン・アンド・カンパニー Improved intradermal delivery of biologically active agents
US20050079152A1 (en) * 2003-06-17 2005-04-14 Bot Adrian Ian Methods of elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
EP2338506A3 (en) * 2003-06-17 2011-10-12 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
PL202927B1 (en) * 2003-07-20 2009-08-31 Carr Daniel R Peptide and pharmaceutical composition as well as their therapeutic applications
JP2007503435A (en) * 2003-08-26 2007-02-22 ベクトン・ディキンソン・アンド・カンパニー Intradermal delivery of therapeutics
WO2005053738A1 (en) * 2003-11-21 2005-06-16 Institut Pasteur Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
KR20070056042A (en) * 2004-06-17 2007-05-31 맨카인드 코포레이션 Epitope analogs
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
MXPA06014769A (en) * 2004-06-17 2007-03-26 Mannkind Corp Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods.
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US8425323B2 (en) * 2004-06-30 2013-04-23 Wms Gaming Inc. Wagering game with asset trading
CN101146550B (en) * 2004-12-29 2013-04-17 曼康公司 Use of immunogenicity composition in preparing kit for initiating and enhancing immune responses
WO2006071983A2 (en) 2004-12-29 2006-07-06 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2006071990A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
EP2351577A1 (en) 2004-12-29 2011-08-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
BRPI0611795A2 (en) * 2005-06-17 2010-09-28 Mannkind Corp multivalent drag-and-amplify immunotherapy for carcinoma
NZ564359A (en) 2005-06-17 2011-09-30 Mannkind Corp Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
CN101198620A (en) * 2005-06-17 2008-06-11 曼康公司 Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
CN101355960A (en) 2005-10-18 2009-01-28 诺华疫苗和诊断公司 Mucosal and systemic immunizations with alphavirus replicon particles
US7855062B2 (en) 2005-12-14 2010-12-21 The Invention Science Fund I, Llc Bone cell delivery device
US9005944B2 (en) 2005-12-14 2015-04-14 The Invention Science Fund I, Llc Bone cell delivery device
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
ES2363891T3 (en) 2006-03-20 2011-08-18 The Regents Of The University Of California ANTIBODIES AGAINST THE ANTIGEN OF TRONCAL CELLS OF THE PROSTATE (PSCA) GENETICALLY MODIFIED FOR ADDRESSING TO CANCER.
US8063063B2 (en) * 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
WO2007109810A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
JP2009544610A (en) * 2006-07-14 2009-12-17 マンカインド コーポレイション Methods for eliciting, enhancing and retaining immune responses against MHC class I restricted epitopes for prophylactic or therapeutic purposes
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
ES2384659T3 (en) * 2007-02-01 2012-07-10 Avantor Performance Materials, Inc. Solutions for the storage of chromatographic media and chromatographic equipment and their use
CA2678353A1 (en) 2007-02-15 2008-08-21 Mannkind Corporation A method for enhancing t cell response
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
MX2009012635A (en) * 2007-05-23 2012-09-13 Mannkind Corp Multicistronic vectors and methods for their design.
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2009039628A1 (en) 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
EP2740490A1 (en) * 2007-10-03 2014-06-11 Cornell University Treatment of proliferative disorders using antibodies to PSMA
ES2712505T3 (en) 2008-04-17 2019-05-13 Pds Biotechnology Corp Stimulation of an immune response by enantiomers of cationic lipids
US20110070298A1 (en) 2008-06-05 2011-03-24 Immunovaccine Technologies Inc. Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
US8156070B2 (en) * 2008-09-05 2012-04-10 Roche Diagnostics Operations, Inc. Insulin pump programming software with basal profile preview feature
ES2712732T3 (en) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Methods and kits for the diagnosis of cancer and the prediction of therapeutic value
CA2778707A1 (en) 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
EP3135302A1 (en) 2009-12-02 2017-03-01 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
JP2013532008A (en) 2010-05-28 2013-08-15 テトリス オンライン インコーポレイテッド Interactive hybrid asynchronous computer game infrastructure
CN113876945A (en) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 Liposome composition comprising adjuvant for activating or increasing TLR2 activity and application thereof
US9149508B1 (en) * 2011-10-26 2015-10-06 Sigmovir Biosystems, Inc. Vaccination by circumventing preexistent immunity
WO2014047533A1 (en) * 2012-09-21 2014-03-27 Frank Bedu-Addo Improved vaccine compositions and methods of use
WO2014143781A1 (en) 2013-03-15 2014-09-18 Camas Incorporated Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities
KR102132697B1 (en) 2013-12-05 2020-07-10 엘지디스플레이 주식회사 Curved Display Device
US10816554B2 (en) 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
US20150343139A1 (en) * 2014-05-30 2015-12-03 Boston Scientific Scimed, Inc. Implantable pumps and related methods of use
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide
SG10201913625XA (en) 2015-08-07 2020-03-30 Imaginab Inc Antigen binding constructs to target molecules
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
CN109715196A (en) 2016-06-13 2019-05-03 转矩医疗股份有限公司 For promoting the composition and method of immune cell function
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
US11524033B2 (en) 2017-09-05 2022-12-13 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
MA52363A (en) 2018-04-26 2021-03-03 Agenus Inc THERMAL SHOCK PROTEIN (HSP) PEPTIDIC COMPOSITIONS AND THEIR METHODS OF USE
WO2020186064A1 (en) * 2019-03-12 2020-09-17 The General Hospital Corporation Highly networked immunogen composition

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3604417A (en) 1970-03-31 1971-09-14 Wayne Henry Linkenheimer Osmotic fluid reservoir for osmotically activated long-term continuous injector device
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4034756A (en) 1971-01-13 1977-07-12 Alza Corporation Osmotically driven fluid dispenser
US3760805A (en) 1971-01-13 1973-09-25 Alza Corp Osmotic dispenser with collapsible supply container
US3732865A (en) 1971-01-13 1973-05-15 Alza Corp Osmotic dispenser
US3760804A (en) 1971-01-13 1973-09-25 Alza Corp Improved osmotic dispenser employing magnesium sulphate and magnesium chloride
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3929132A (en) 1973-04-10 1975-12-30 Alza Corp Osmotic dispenser
US3995632A (en) 1973-05-04 1976-12-07 Alza Corporation Osmotic dispenser
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4286067A (en) 1978-10-23 1981-08-25 Alza Corporation Article of manufacture comprising semipermeable polymer and dextran derivative
US4304232A (en) 1979-03-14 1981-12-08 Alza Corporation Unit system having multiplicity of means for dispensing useful agent
US4450198A (en) 1980-01-28 1984-05-22 Alza Corporation Microporous film with polymer in pores for regulating passage of fluid
US4439199A (en) 1980-02-19 1984-03-27 Alza Corporation Method for administering immunopotentiator
US4455142A (en) * 1980-07-07 1984-06-19 Alza Corporation Method of coadministering an antigen and an immunopotentiator
US4300558A (en) 1980-07-18 1981-11-17 Alza Corporation Self-driven fluid dispenser
US4350271A (en) 1980-08-22 1982-09-21 Alza Corporation Water absorbing fluid dispenser
US4367741A (en) 1980-12-22 1983-01-11 Alza Corporation Dispenser powered by cross-linked hydrophilic polymer grafted to hydrophilic polymer
US4340054A (en) 1980-12-29 1982-07-20 Alza Corporation Dispenser for delivering fluids and solids
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4340048A (en) 1981-03-28 1982-07-20 Alza Corporation Self-driven hypodermic injector
US4455145A (en) 1981-07-10 1984-06-19 Alza Corporation Dispensing device with internal drive
IT1142930B (en) 1981-11-04 1986-10-15 Luigi Bernardi PORTABLE APPARATUS THAT INFUSES INSULIN ON THE BASIS OF GLYCEMIC DETECTION
US4474575A (en) 1982-02-01 1984-10-02 Alza Corporation Self-driven pump assembly and method of operation
US4435173A (en) 1982-03-05 1984-03-06 Delta Medical Industries Variable rate syringe pump for insulin delivery
US4778879A (en) 1982-04-20 1988-10-18 Sloan-Kettering Institute For Cancer Research Highly purified human interleukin 2 and method
US4498843A (en) 1982-08-02 1985-02-12 Schneider Philip H Insulin infusion pump
US4753651A (en) 1982-08-30 1988-06-28 Alza Corporation Self-driven pump
US4619652A (en) 1982-12-23 1986-10-28 Alza Corporation Dosage form for use in a body mounted pump
US4561856A (en) 1983-08-18 1985-12-31 Cochran Ulrich D Infusion pump
US4552651A (en) 1983-11-14 1985-11-12 Conoco Inc. Control of froth cell performance through the use of differential bubbler tubes
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4908433A (en) 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
NL8403937A (en) 1984-12-24 1986-07-16 Cornelis Smit DEVICE FOR DELIVERING A NUMBER OF LIQUID DOSES.
DE3937412A1 (en) 1989-11-10 1991-05-16 Hoechst Ag SYNTHETIC VACCINE FOR THE SPECIFIC INDUCTION OF CYTOTOXIC T-LYMPHOZYTES
US4865598A (en) 1985-08-16 1989-09-12 Alza Corporation Dispensing system for administering beneficial agent
US4963141A (en) 1985-08-16 1990-10-16 Alza Corporation Dispensing system for administering beneficial agent formulation to ruminants
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US5019384A (en) * 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
US4838862A (en) 1986-08-04 1989-06-13 Pharmetrix Corp. Portable controlled release osmotic infusion device
DE3700119A1 (en) * 1987-01-03 1988-07-14 Inst Diabetestechnologie Gemei IMPLANTABLE ELECTROCHEMICAL SENSOR
US5023088A (en) 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
GB2211132B (en) * 1987-10-22 1991-08-14 Gore & Ass Bagpipes and a pipe bag therefor
US4872873A (en) 1987-12-14 1989-10-10 Merck & Co., Inc. Controlled release bolus device
US4855141A (en) 1988-03-25 1989-08-08 Alza Corporation Device comprising means for protecting and dispensing fluid sensitive medicament
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US4898582A (en) 1988-08-09 1990-02-06 Pharmetrix Corporation Portable infusion device assembly
US4929233A (en) 1988-08-26 1990-05-29 Alza Corporation Implantable fluid imbibing pump with improved closure
US5135523A (en) 1988-12-13 1992-08-04 Alza Corporation Delivery system for administering agent to ruminants and swine
US5174999A (en) 1988-12-13 1992-12-29 Alza Corporation Delivery system comprising fluid ingress and drug egress
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5110596A (en) 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5037420A (en) 1988-12-13 1991-08-06 Alza Corporation Delivery system comprising two sections for delivering somatotropin
US4976966A (en) 1988-12-29 1990-12-11 Alza Corporation Delayed release osmotically driven fluid dispenser
PL159857B1 (en) 1989-01-20 1993-01-29 Method for the continuous control of the carried infusion microbatcher
US4929141A (en) * 1989-02-21 1990-05-29 International Baler Corp. Bale-opening method and apparatus
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5110598A (en) * 1989-06-30 1992-05-05 Smithkline Beecham Corp. Intermittent release dosage form
US5030216A (en) 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5135498A (en) 1990-04-02 1992-08-04 Kam Robert J Controlled release infusion device
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5257987A (en) 1990-05-21 1993-11-02 Pharmetrix Corporation Controlled release osmotic infusion system
US5169390A (en) 1990-05-21 1992-12-08 Athayde Amulya L Osmotic infusion device
AU8074591A (en) 1990-06-15 1992-01-07 Cortrak Medical, Inc. Drug delivery apparatus and method
US5766601A (en) * 1990-08-08 1998-06-16 University Of Massachusetts Medical Center Cross-reactive influenza a immunization
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
GB9027422D0 (en) * 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
DE4143467C2 (en) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptide motif and its use
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5451504A (en) 1991-07-29 1995-09-19 Serex, Inc. Method and device for detecting the presence of analyte in a sample
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US5304165A (en) 1991-12-09 1994-04-19 Habley Medical Technology Corporation Syringe-filling medication dispenser
US5223265A (en) 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US5209746A (en) 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5221278A (en) 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
DE4238416A1 (en) 1992-11-13 1994-05-19 Max Planck Gesellschaft Determination of peptide motifs on MHC molecules
US5744316A (en) 1992-12-22 1998-04-28 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
WO1994018954A1 (en) 1993-02-22 1994-09-01 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of biologics and compositions useful therefor
WO1994021680A1 (en) 1993-03-17 1994-09-29 The Government Of The United States Of America As Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5409710A (en) * 1993-04-20 1995-04-25 Endocon, Inc. Foam cell drug delivery
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5368562A (en) 1993-07-30 1994-11-29 Pharmacia Deltec, Inc. Systems and methods for operating ambulatory medical devices such as drug delivery devices
US5595871A (en) * 1993-08-25 1997-01-21 University Of Scranton Detection and prevention of mycoplasma hominis infection
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
KR100372375B1 (en) 1993-12-23 2003-04-21 머클한스피터 Immunological response potentiation process
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5478556A (en) 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US5496360A (en) 1994-04-12 1996-03-05 Ventritex, Inc. Implantable cardiac electrode with rate controlled drug delivery
DE4423392A1 (en) 1994-07-04 1996-01-11 Birsner & Grob Biotech Gmbh Methods of identifying antigenic peptides
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
EP0812355A2 (en) 1995-02-28 1997-12-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Agent for treating tumours and other hyperplasia
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5935568A (en) 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US5900238A (en) 1995-07-27 1999-05-04 Immunex Corporation Vaccine delivery system
JPH09151200A (en) 1995-09-29 1997-06-10 Ajinomoto Co Inc Peptide capable of inducing immune response to human gastric cancer, therapeutic and preventive agent for human gastric cancer containing the same
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
NZ333203A (en) 1996-06-07 2000-07-28 Kyogo Itoh Tumour antigen proteins, genes thereof, and tumour antigen peptides
US5837231A (en) * 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
US5951975A (en) 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
US5876972A (en) 1996-09-23 1999-03-02 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6204250B1 (en) * 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
ATE203157T1 (en) 1996-12-20 2001-08-15 Alza Corp INJECTABLE DEPOSIT GEL PREPARATION AND PRODUCTION METHOD
PT973499E (en) 1997-03-31 2003-12-31 Alza Corp IMPLANTABLE DIFFUSER ADMINISTRATION SYSTEM
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
PT1003548E (en) * 1997-07-10 2006-09-29 Mannkind Corp DEVICE FOR THE INDUCTION OF A CTL RESPONSE
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20030215425A1 (en) 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
CA2405363A1 (en) 2000-04-28 2001-11-08 Ctl Immunotherapies Corp. Epitope synchronization in antigen presenting cells
CN100589845C (en) 2001-03-07 2010-02-17 麦康公司 Anti-neovasculature preparations for cancer
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
ES2358642T3 (en) 2001-11-07 2011-05-12 Mannkind Corporation EXPRESSION VECTORS CODING ANTIGENS EPITHOPES AND METHODS FOR THEIR DESIGN.
JP2005537800A (en) * 2002-09-06 2005-12-15 マンカインド コーポレイション Epitope sequence
US20050079152A1 (en) 2003-06-17 2005-04-14 Bot Adrian Ian Methods of elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
EP2338506A3 (en) 2003-06-17 2011-10-12 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
KR20070056042A (en) 2004-06-17 2007-05-31 맨카인드 코포레이션 Epitope analogs
MXPA06014769A (en) 2004-06-17 2007-03-26 Mannkind Corp Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods.
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US7678050B2 (en) * 2004-08-24 2010-03-16 General Electric Company Method and apparatus for detecting cardiac events
WO2006071983A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
CN101146550B (en) 2004-12-29 2013-04-17 曼康公司 Use of immunogenicity composition in preparing kit for initiating and enhancing immune responses
EP2351577A1 (en) 2004-12-29 2011-08-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
WO2006071990A2 (en) 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
BRPI0611795A2 (en) 2005-06-17 2010-09-28 Mannkind Corp multivalent drag-and-amplify immunotherapy for carcinoma
CN101198620A (en) 2005-06-17 2008-06-11 曼康公司 Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
NZ564359A (en) 2005-06-17 2011-09-30 Mannkind Corp Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
JP2009544610A (en) * 2006-07-14 2009-12-17 マンカインド コーポレイション Methods for eliciting, enhancing and retaining immune responses against MHC class I restricted epitopes for prophylactic or therapeutic purposes
CA2678353A1 (en) 2007-02-15 2008-08-21 Mannkind Corporation A method for enhancing t cell response
MX2009012635A (en) 2007-05-23 2012-09-13 Mannkind Corp Multicistronic vectors and methods for their design.

Also Published As

Publication number Publication date
WO2002062368A2 (en) 2002-08-15
US20120046638A1 (en) 2012-02-23
US8372393B2 (en) 2013-02-12
US6977074B2 (en) 2005-12-20
US20060153858A1 (en) 2006-07-13
US7364729B2 (en) 2008-04-29
AU9743201A (en) 2002-08-08
US20020007173A1 (en) 2002-01-17
AU784923B2 (en) 2006-07-27
AU2002247023A1 (en) 2002-08-19
US20090035252A1 (en) 2009-02-05
WO2002062368A3 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
WO2002062368A8 (en) Method of inducing a ctl response
WO2002032406A3 (en) Methods and products related to pulmonary delivery of polysaccharides
NZ502168A (en) Inducing and maintaining a CTL response by delivering antigen to the lymphatic system of a mammal via an external apparatus
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
WO2001034801A3 (en) Recombinant gelatin in vaccines
ATE540697T1 (en) STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM
NZ562998A (en) Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB9818627D0 (en) Improvements in dva vaccination
NZ504894A (en) Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
DE69739253D1 (en) LIPOSOMAL GRIP VACCINE AND METHOD
EP1184370A3 (en) Compounds with growth hormone releasing properties
WO2003080111A3 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
ATE346606T1 (en) NERVE GROWTH FACTOR AS A VACCINE ADJUVANT
WO2001051008A3 (en) Selective activation of a th1 or th2 lymphocyte regulated immune response
WO2005122739A3 (en) Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
AU6721801A (en) The use of plant oil-bodies in vaccine delivery systems
ATE78403T1 (en) VACCINE AGAINST MASTITIS.
HK1045209A1 (en) A vibrator and a method of controlling a vibrator.
WO2005028513A3 (en) High-yield method for the production of human antibodies blocking the biological activity of a human cytokine
WO2003011395A3 (en) Method of utilizing neurotrophins to manipulate reproductive capacity
WO2001034185A3 (en) Induction of mucosal immunity by vaccination via the skin route
WO2002032455A3 (en) Vaccine
EP1197889A4 (en) Schedule communication method, apparatus, and system
EP1168273A3 (en) Device controller and control arrangement
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 33/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

Free format text: IN PCT GAZETTE 33/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP